SEC Form 4 · accession 0001104659-26-107120
Transcode Therapeutics, Inc. · RNAZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas A Fitzgerald
Officer — Chief Financial Officer · Director
Period of report
Sep 9, 2026
Accepted (ET)
Sep 11, 2026 · 5:10 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001829635
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $1.78 | Sep 9, 2026 | A | 185,000 | A | — | Sep 8, 2036 | Common Stock | 185,000 | 185,000 | D |
Explanation of responses
- F1The shares underlying this option shall vest and become exercisable in twelve (12) equal monthly installments following the grant date.